What is it about?
Currently,although several clinical trials available give strong suggestions that extension of endocrine therapy has benefits, the risk level at which patients may benefit from extended endocrine therapy remains uncertain. We conducted this study to identify the amount of patients at a substantial risk of late recurence after 5-year adjuvant endocrine therapy that might benefit from extended endocrine therapy.
Featured Image
Why is it important?
Our findings show that late relapse after completion of 5-year adjuvant endocrine therapy was still common, grade 3 and more than 3 positive nodes were risk factors of late recurrence, while grade 3 was the only risk factor of late distant metastasis, these patients might benefit from extended endocrine therapy.
Perspectives
Writing this article was a great pleasure as it has co-authors with whom I have had long standing collaborations. This article may also give suggestions to clinicians and patients with uncertainty about whether to continue endocrine therapy after 5-year adjuvant endocrine therapy.
Junming Xu
Read the Original
This page is a summary of: ER-positive breast cancer patients with more than three positive nodes or grade 3 tumors are at high risk of late recurrence after 5-year adjuvant endocrine therapy, OncoTargets and Therapy, October 2017, Dove Medical Press,
DOI: 10.2147/ott.s142698.
You can read the full text:
Contributors
The following have contributed to this page
